Ophthalmic compositions for treating ocular hypertension
AssigneeMerck & Co., Inc.
InventorsJames B. Doherty, Meng-Hsin Chen, Luping Liu, Swaminathan R. Natarajan, Robert M. Tynebor
Life of this patent
Estimating the term…
Abstract
This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Claims4
A method for treating ocular hypertension or glaucoma comprising administration to a patient in need of such treatment a therapeutically effective amount of a compound of structural formula I:
- or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof:
- wherein,
- R represents hydrogen, or C1-6 alkyl;
- X represents —(CHR7)p—, —(CHR7)pCO—;
- Y represents —CO(CH2)n—, CH2, or —CH(OR)—;
- Q represents CRy;
- Ry represents H, or C1-6 alkyl;
- Rw represents H, C1-6 alkyl, —C(O)C1-6 alkyl, —C(O)OC1-6 alkyl, —SO2N(R)2, —SO2C1-6 alkyl, —SO2C6-10 aryl, NO2, CN or —C(O)N(R)2;
- R2 represents hydrogen, C1-10 alkyl, OH, C2-6 alkenyl, C1-6 alkylSR, —(CH2)n—O(CH2)mOR, —(CH2)nC1-6 alkoxy, —(CH2)nC3-8 cycloalkyl, —(CH2)nC3-10 heterocyclyl, —N(R)2, —COOR, or —(CH2)nC6-10 aryl, said alkyl, heterocyclyl, or aryl optionally substituted with 1-3 groups selected from Ra;
- R3 represents hydrogen, C1-10 alkyl, —(CH2)nC3-8 cycloalkyl, —(CH2)nC3-10 heterocyclyl, —(CH2)nCOOR, —(CH2)nC6-10 aryl, —(CH2)nNHR8, —(CH2)nN(R)2, —(CH2)nN(R8)2, —(CH2)nNHCOOR, —(CH2)nN(R8)CO2R, —(CH2)nN(R8)COR, —(CH2)nNHCOR, —(CH2)nCONH(R8), aryl, —(CH2)nC1-6 alkoxy, CF3, —(CH2)nSO2R, —(CH2)nSO2N(R)2, —(CH2)nCON(R)2, —(CH2)nCONHC(R)3, —(CH2)nCONHC(R)2CO2R, —(CH2)nCOR8, nitro, cyano or halogen, said alkyl, alkoxy, heterocyclyl, or aryl optionally substituted with 1-3 groups of Ra;
- or R2 and R3 taken together with the intervening Q form a 3-10 membered carbocyclic or heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from Ra;
- or R2 and R3 taken together with the intervening Q represent OR;
- R4 and R5 independently represent hydrogen, C1-6 alkoxy, OH, C1-6 alkyl, COOR, SOqC1-6 alkyl, COC1-6 alkyl, SO3H, —O(CH2)nN(R)2, —O(CH2)nCO2R, —OPO(OH)2, CF3, OCF3—N(R)2, nitro, cyano, C1-6 alkylamino, or halogen;
- and
- R6 represents hydrogen, C1-10 alkyl, —(CH2)nC6-10 aryl, NRcRd, —NR(CH2)nC6-10 aryl, —N((CH2)nC6-10 aryl), —(CH2)nC3-10 heterocyclyl, —NR(CH2)nC3-10 heterocyclyl, —N((CH2)nC3-10 heterocyclyl)2 (C6-10 aryl)O—, —(CH2)nC3-8 cycloalkyl, —COOR, —C(O)CO2R, said aryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from Ra, wherein the Ra(s) can be attached to any carbon atom or heteroatom selected from N and 5;
- Rc and Rd independently represent H, C1-6 alkyl, C2-6 alkenyl, C1-6 alkylSR, —(CH2)nO(CH2)mOR, —(CH2)nC1-6 alkoxy, or —(CH2)nC3-8 cycloalkyl;
- or Rc and Rd taken together with the intervening N atom form a 4-10 membered heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from Ra;
- R7 represents hydrogen, C1-6 alkyl, —(CH2)nCOOR or —(CH2)nN(R)2,
- R8 represents —(CH2)nC3-8 cycloalkyl, —(CH2)n 3-10 heterocyclyl, C1-6 alkoxy or —(CH2)nC5-10 heteroaryl, —(CH2)nC6-10 aryl said heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from Ra;
- Ra represents F, Cl, Br, I, CF3, N(R)2, NO2, CN, —O—, —COR8, —CONHR8, —CON(R8)2, —O(CH2)nCOOR, —NH(CH2)nOR, —COOR, OCF3, CF2CH2OR, —NHCOR, —SO2R, —SO2NR2, —SR, (C1-C6 alkyl)O—, —(CH2)nO(CH2)mOR, —(CH2)nC1-6 alkoxy, (aryl)O—, —(CH2)nOH, (C1-C6 alkyl)S(O)m—, H2N—C(NH)—, (C1-C6 alkyl)C(O)—, (C1-C6 alkyl)OC(O)NH—, —(C1-C6 alkyl)NRw(CH2)nC3-10 heterocyclyl-Rw, —(C1-C6 alkyl)O(CH2)nC3-10 heterocyclyl-Rw, —(C1-C6 alkyl)S(CH2)nC3-10 heterocyclyl-Rw, —(C1-C6 alkyl)-C3-10 heterocyclyl-Rw, —(CH2)n—Z1—C(═Z2)N(R)2, —(C2-6 alkenyl)NRw(CH2)nC3-10 heterocyclyl-Rw, —(C2-6 alkenyl)O(CH2)nC3-10 heterocycyl-R, —(C2-6 alkenyl)S(CH2)nC3-10 heterocyclyl-Rw, —(C2-6 alkenyl)-C3-10 heterocyclyl-Rw, —(C2-6 alkenyl)-Z1—C(═Z2)N(R)2, —(CH2)nSO2R, —(CH2)nSO3H, —(CH2)nPO(OR)2, C3-10cycloalkyl, C6-10 aryl, C3-10 heterocyclyl, C2-6 alkenyl, and C1-C10 alkyl, said alkyl, alkenyl, alkoxy, heterocyclyl and aryl optionally substituted with 1-3 groups selected from C1-C6 alkyl, halogen, (CH2)nOH, CN, NO2, CON(R)2 and COOR;
- Z1 and Z2 independently represents NRw, O, CH2, or S;
- m is 0-3;
- n is 0-3;
- p is 0-3 and
- q is 0-2.
A method for treating macular edema, macular degeneration, increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve oxygen tension, and/or a neuroprotective effect comprising administration to a patient in need of such treatment a pharmaceutically effective amount of a compound of structural formula I:
- or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof:
- wherein,
- R represents hydrogen, or C1-6 alkyl;
- X represents —(CHR7)p—, —(CHR7)pCO;
- Y represents —CO(CH2)n—, CH2, or —CH(OR)—;
- Q represents CRy;
- Ry represents H, or C1-6 alkyl;
- Rw represents H, C1-6 alkyl, —C(O)C1-6 alkyl, —C(O)OC1-6 alkyl, —SO2N(R)2, —SO2C1-6 alkyl, —SO2C6-10 aryl, NO2, CN or —C(O)N(R)2;
- R2 represents hydrogen, C1-10 alkyl, OH, C2-6 alkenyl, C1-6 alkylSR, —(CH2)n—O(CH2)mOR, —(CH2)nC1-6 alkoxy, —(CH2)nC3-8 cycloalkyl, —(CH2)nC3-10 heterocyclyl, —N(R)2, —COOR, or —(CH2)nC6-10 aryl, said alkyl, heterocyclyl, or aryl optionally substituted with 1-3 groups selected from Ra;
- R3 represents hydrogen, C1-10 alkyl, —(CH2)nC3-8 cycloalkyl, —(CH2)nC3-40 heterocyclyl, —(CH2)nCOOR, —(CH2)nC6-10 aryl, —(CH2)nNHR8, —(CH2)nN(R)2, —(CH2)nN(R8)2, —(CH2)nNHCOOR, —(CH2)nN(R8)CO2R, —(CH2)nN(R8)COR, —(CH2)nNHCOR, —(CH2)nCONH(R8), aryl, —(CH2)nC1-6 alkoxy, CF3, —(CH2)nSO2R, —(CH2)nSO2N(R)2, —(CH2)nCON(R)2, —(CH2)nCONHC(R)3, —(CH2)nCONHC(R)2CO2R, —(CH2)nCOR8, nitro, cyano or halogen, said alkyl, alkoxy, heterocyclyl, or aryl optionally substituted with 1-3 groups of Ra;
- or R2 and R3 taken together with the intervening Q form a 3-10 membered carbocyclic or heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from Ra;
- or R2 and R3 taken together with the intervening Q represent OR;
- R4 and R5 independently represent hydrogen, C1-6 alkoxy, OH, C1-6 alkyl, COOR, SOqC1-6 alkyl, COC1-6 alkyl, SO3H, —O(CH2)nN(R)2, —O(CH2)nCO2R, —OPO(OH)2, CF3, OCF3—N(R)2, nitro, cyano, C1-6 alkylamino, or halogen;
- and
- R6 represents hydrogen, C1-10 alkyl, —(CH2)nC6-10 aryl, NRcRd, —NR(CH2)nC6-10 aryl, —N((CH2)nC6-10 aryl)2, —(CH2)nC3-10 heterocyclyl, —NR(CH2)nC3-10 heterocyclyl, —N((CH2)nC3-10 heterocyclyl)2(C6-10 aryl)O—, —(CH2)nC3-8 cycloalkyl, —COOR, —C(O)CO2R, said aryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from Ra, wherein the Ra(s) can be attached to any carbon atom or heteroatom selected from N and S;
- Rc and Rd independently represent H, C1-6 alkyl, C2-6 alkenyl, C1-6 alkylSR, —(CH2)nO(CH2)mOR, —(CH2)nC1-6 alkoxy, or —(CH2)nC3-8 cycloalkyl;
- or Rc and Rd taken together with the intervening N atom form a 4-10 membered heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from Ra;
- R7 represents hydrogen, C1-6 alkyl, —(CH2)nCOOR or —(CH2)nN(R)2,
- R8 represents —(CH2)nC3-8 cycloalkyl, —(CH2)n 3-10 heterocyclyl, C1-6 alkoxy or —(CH2)nC51o heteroaryl, —(CH2)nC6-10 aryl said heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from Ra;
- Ra represents F, Cl, Br, I, CF3, N(R)2, NO2, CN, —O—, —COR8, —CONHR8, —CON(R8)2, —O(CH2)nCOOR, —NH(CH2)nOR, COOR, —OCF3, CF2CH2OR, NHCOR, SO2R, SO2NR2, SR, (C1-C6 alkyl)O—, —(CH2)n—O(CH2)mOR, —(CH2)nC1-6 alkoxy, (aryl)O—, —(CH2)nOH, (C1-C6 alkyl)S(O)m—, H2N—C(NH)—, (C1-C6 alkyl)C(O)—, (C1-C6 alkyl)OC(O)NH—, —(C1-C6 alkyl)NRw(CH2)nC3-10 heterocyclyl-Rw, —(C1-C6 alkyl)O(CH2)nC3-10 heterocyclyl-Rw, —(C1-C6 alkyl)S(CH2)nC3-10 heterocyclyl-Rw, —(C1-C6 alkyl)-C3-10 heterocyclyl-Rw, —(CH2)n—Z1C(═Z2)N(R)2, —(C2-6 alkenyl)NRw(CH2)nC3-10 heterocyclyl-Rw, —(C2-6 alkenyl)O(CH2)nC3-10 heterocyclyl-Rw, —(C2-6 alkenyl)S(CH2)nC3-10 heterocyclyl-Rw, —(C2-6 alkenyl)-C3-10 heterocyclyl-Rw, —(C2-6 alkenyl)-Z1—C(═Z2)N(R)2, —(CH2)nSO2R, —(CH2)nSO3H, —(CH2)nPO(OR)2, C3-10 cycloalkyl, C6-10 aryl, C3-10 heterocyclyl, C2-6 alkenyl, and C1-C10 alkyl, said alkyl, alkenyl, alkoxy, heterocyclyl and aryl optionally substituted with 1-3 groups selected from C1-C6 alkyl, halogen, (CH2)nOH, CN, NO2, CON(R)2 and COOR;
- Z1 and Z2 independently represents NR, O, CH2, or S;
- m is 0-3;
- n is 0-3;
- p is 0-3 and
- q is 0-2.
Dependencies are inferred from the claim text.